rs12101255 — TSHR

Intronic regulatory variant in TSHR intron 1; the T allele disrupts thymic expression of the TSH receptor, allowing autoreactive T cells to escape tolerance and increasing susceptibility to Graves' disease — the most common autoimmune cause of hyperthyroidism

See your personal result for TSHR

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

TSHR Intron 1 — Where Tolerance Fails

The thyroid stimulating hormone receptor sits at the centre of the thyroid axis. TSH released by the pituitary binds TSHR on thyroid follicular cells, driving production of T3 and T4. In Graves' disease — the most common autoimmune cause of hyperthyroidism — the immune system generates stimulating autoantibodies (TRAbs) that bind TSHR and permanently mimic TSH, overriding the pituitary's feedback control. rs12101255 is an [intronic regulatory SNP | A variant within a non-coding intron that influences when, where, and how much of the TSHR protein is made] in intron 1 of TSHR that influences whether the thymus — the organ where immune self-tolerance is trained — adequately presents TSHR to developing T cells. When TSHR expression in the thymus is reduced, autoreactive T cells that would normally be deleted can escape into the circulation, where they can seed the autoimmune response.

The Mechanism

TSHR intron 1 contains a regulatory element that controls tissue-restricted expression of the receptor, including in thymic epithelial cells. A landmark 2014 PNAS study by Stefan et al.11 Stefan et al.
Genetic-epigenetic dysregulation of thymic TSH receptor gene expression triggers thyroid autoimmunity identified an open chromatin region overlapping rs12101255 and the adjacent rs12101261 in this intron. In cells stimulated with interferon-alpha — released during viral infection — histone H3 lysine 4 methylation (H3K4me1) is enriched at this region, and the transcriptional repressor PLZF binds specifically at the disease-susceptibility allele. The net effect: individuals carrying the risk genotype show measurably reduced intrathymic TSHR expression compared with protective-allele carriers. Fewer TSHR-presenting thymic cells means fewer autoreactive T cells are clonally deleted, allowing them to persist and, under the right environmental trigger, attack the thyroid.

This also explains the well-known viral-trigger pattern in Graves' disease: interferons induced by viral infection epigenetically activate PLZF binding at the risk allele, acutely suppressing thymic TSHR, and providing a mechanistic link between infection and autoimmune onset.

The variant also correlates with reduced full-length TSHR mRNA relative to splice variants in thyroid tissue itself, suggesting dual dysregulation — both in tolerance training and in the receptor's eventual expression in the thyroid.

The Evidence

The rs12101255–Graves' disease association was established convincingly by Brand et al. in Human Molecular Genetics22 Brand et al. in Human Molecular Genetics
A systematic SNP analysis across an 800 kb region spanning TSHR, 768 GD cases and 768 matched controls, European descent (2009): OR 1.55, 95% CI 1.33–1.81, P = 1.95×10⁻⁷. The risk direction was replicated in three independent European cohorts by Płoski et al.33 Płoski et al.
Warsaw, Gliwice, and UK cohorts; the UK arm alone comprised 2,504 patients and 2,784 controls — one of the largest single-study samples for this locus (2010), with ORs of 1.47–1.87 and p-values reaching 3.68×10⁻²¹.

A meta-analysis of seven articles (5,754 GD cases, 5,768 controls)44 meta-analysis of seven articles (5,754 GD cases, 5,768 controls)
Including Chinese, Japanese, Polish, UK, and Brazilian populations quantified the per-genotype risk: T vs C allele OR 1.50 (95% CI 1.40–1.60); TT vs CC OR 2.22 (95% CI 1.92–2.57); carriers of at least one T allele (CT+TT) had OR 1.66 versus CC. A second large meta-analysis from 2016 (4,790 cases, 5,350 controls) confirmed TT+CT vs CC OR 1.67 (95% CI 1.53–1.83, I²=0%), with no between-study heterogeneity — an unusually consistent cross-population signal.

The variant does not appear to differentiate Graves' disease from Graves' ophthalmopathy (the eye manifestation): the SNP predicts overall Graves' susceptibility but not the orbital complication specifically.

Practical Actions

TT homozygotes face approximately 2.2-fold elevated Graves' disease risk. Graves' disease is highly treatable — the priority for TT and CT carriers is early recognition of hyperthyroid symptoms rather than prophylaxis, and awareness of triggers including viral illness and excess iodine intake.

Thyroid peroxidase antibodies (TPO-Ab) and TSH receptor antibodies (TRAb) are the earliest detectable biomarkers of thyroid autoimmunity, often present years before clinical hyperthyroidism. TT carriers benefit from knowing their baseline thyroid function and antibody status.

Selenium at 100–200 mcg/day has been shown in RCTs to reduce autoimmune thyroid activity and TRAb titres. Since the TSHR intron 1 risk variants appear to lower the immune tolerance threshold specifically at this antigen, reducing the overall autoimmune burden through selenium's immunomodulatory effects is a targeted intervention for T allele carriers.

Interactions

rs12101255 and rs179247 are the two most-studied SNPs in TSHR intron 1; they are in linkage disequilibrium and are frequently studied as a haplotype pair. Carrying risk alleles at both loci may carry higher Graves' disease susceptibility than either alone. rs12101261, the immediately adjacent SNP that shares the same open chromatin region, is structurally the closest functional partner.

Beyond the TSHR locus, Graves' disease has strong HLA associations (DRB1, DQA1), PTPN22 R620W (rs2476601), and CTLA4 variants (rs3087243, rs231775) as independent susceptibility loci — these act through T-cell activation thresholds independently of the thymic TSHR expression mechanism captured by rs12101255.

Genotype Interpretations

What each possible genotype means for this variant.

CC Typical Graves' Risk Normal

Standard Graves' disease susceptibility — protective C allele at both copies

You carry two copies of the C allele at rs12101255 — the lower-risk genotype at the TSHR intron 1 locus. Approximately 39% of people globally share this genotype (slightly more common in Europeans and South Asians). Your thymic expression of the TSH receptor is not impaired by the T allele regulatory variant, meaning your immune system's central tolerance training for TSHR proceeds normally at this locus. This does not eliminate Graves' disease risk — other genetic and environmental factors also contribute — but TSHR intron 1 does not add risk for you.

CT One Risk Allele Intermediate

One T risk allele — modestly elevated Graves' disease susceptibility

The codominant inheritance pattern documented across multiple European cohorts means that CT heterozygotes occupy the intermediate risk tier. Your absolute lifetime risk from this single locus remains modest, but CT carriage becomes more clinically significant when combined with other Graves' susceptibility variants in HLA, PTPN22, or CTLA4.

Graves' disease is the most common cause of hyperthyroidism, affecting roughly 1–2% of women and 0.1–0.2% of men across their lifetime. The environmental trigger most mechanistically linked to this specific SNP is viral infection (via interferon-alpha), which epigenetically enhances the T allele's suppression of thymic TSHR expression. High iodine intake, smoking, and postpartum immune rebound are independent Graves' triggers.

TT Two Risk Alleles High Risk

Two T risk alleles — substantially elevated Graves' disease susceptibility (~2.2-fold vs CC)

The TT genotype at rs12101255 confers the highest risk at the TSHR intron 1 locus. The two T alleles create a regulatory configuration in TSHR intron 1's open chromatin region that is maximally responsive to PLZF repressor binding when immune signalling is activated by viral infection (via interferon-alpha). This means both copies of your TSHR intron 1 are susceptible to the PLZF-mediated suppression of thymic TSHR expression — both reducing the central tolerance checkpoint for TSHR-reactive T cells simultaneously.

Graves' disease manifests as diffuse thyroid enlargement (goitre), hyperthyroidism, and in 25–30% of patients, Graves' ophthalmopathy — proptosis, periorbital swelling, and diplopia. While the TT genotype at rs12101255 is not specifically associated with ophthalmopathy severity (the SNP predicts susceptibility to GD itself, not the orbital complication), early treatment that controls thyroid hormone levels limits the cytokine environment that drives orbital fibroblast activation.

The T allele frequency is notably higher in East Asian populations (~62%) than in Europeans (~34%), consistent with the higher prevalence of Graves' disease in East Asian women.

Graves' disease is also a known risk factor for subsequent osteoporosis (from thyroid hormone excess reducing bone density) and atrial fibrillation (from cardiac effects of sustained hyperthyroidism) — two reasons why rapid diagnosis and treatment matter.